Target FGF23, the underlying cause of chronic hypophosphatemia in TIO

CRYSVITA® (burosumab-twza) is the first and only FDA-approved therapy targeting excess fibroblast growth factor 23 (FGF23) in patients with tumor-induced osteomalacia (TIO) associated with tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

CRYSVITA for TIO

What is TIO?

Tumor-induced osteomalacia is an acquired form of hypophosphatemia resulting in osteomalacia. TIO may also be called oncogenic osteomalacia.

Learn About TIO

How CRYSVITA may work

Learn about CRYSVITA’s proposed mechanism of action (MOA) on excess fibroblast growth factor 23 (FGF23)

View the Proposed MOA

CRYSVITA® (burosumab-twza) is the first and only therapy that targets excess FGF23, the underlying cause of chronic hypophosphatemia in TIO

CRYSVITA® (burosumab-twza)— fgf23 antibody

Help your patients gain access to CRYSVITA

UltraCare® Patient Services for CRYSVITA is a program that provides information about how you and your patients can access CRYSVITA. Our services are designed to help patients and caregivers understand their insurance coverage and determine their eligibility for financial and patient assistance programs.

Visit UltraCare
Reference
  1. CRYSVITA (burosumab-twza) US Prescribing Information; June 2020.